A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma

Trial Profile

A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Mar 2014

At a glance

  • Drugs Ridaforolimus (Primary)
  • Indications Ewing's sarcoma; Leiomyosarcoma; Liposarcoma; Osteosarcoma; Sarcoma; Soft tissue sarcoma
  • Focus Therapeutic Use
  • Sponsors ARIAD Pharmaceuticals; Merck Sharp & Dohme
  • Most Recent Events

    • 23 Jan 2013 Primary endpoint added as reported by ClinicalTrials.gov.
    • 06 Oct 2009 Actual end date (1 Aug 2009) added as reported by ClinicalTrials.gov.
    • 06 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top